Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
Portfolio Pulse from
Ultragenyx reported a 42% increase in total revenue for Q3 2024, reaching $139 million. This includes $98 million from Crysvita® and $21 million from Dojolvi®.
November 05, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx's Q3 2024 revenue increased by 42% to $139 million, with significant contributions from Crysvita® and Dojolvi®. This strong performance may positively impact the stock price.
The 42% revenue growth indicates strong demand and successful sales strategies for Ultragenyx's products, Crysvita® and Dojolvi®. This financial performance is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100